BE
MCID: BRR013
MIFTS: 54

Barrett Esophagus/esophageal Adenocarcinoma (BE) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett Esophagus/esophageal Adenocarcinoma

Aliases & Descriptions for Barrett Esophagus/esophageal Adenocarcinoma:

Name: Barrett Esophagus/esophageal Adenocarcinoma 54 13
Barrett Esophagus 54 12 50 24 66 52 42 69
Barrett's Esophagus 12 50 29 14
Adenocarcinoma of Esophagus 24 56 69
Barrett's Ulcer of Esophagus 12 69
Barrett Metaplasia 24 66
Chronic Peptic Ulcer and Esophagitis Syndrome 50
Barrett's Esophagus with Esophagitis 12
Malignant Neoplasm of Esophagus 69
Esophageal Adenocarcinoma 56
Esophagitis-Peptic Ulcer 50
Columnar-Like Esophagus 50
Esophageal Carcinoma 69
Barrett's Oesophagus 12
Esophageal Neoplasms 69
Esophageal Cancer 24
Barretts Syndrome 12
Barrett Syndrome 50
Barrett Ulcer 50
Cle 12
Be 66

Characteristics:

Orphanet epidemiological data:

56
adenocarcinoma of esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: adult;

HPO:

32
barrett esophagus/esophageal adenocarcinoma:
Inheritance somatic mutation


Classifications:



External Ids:

OMIM 54 614266
Disease Ontology 12 DOID:9206
ICD9CM 35 530.85
MeSH 42 D001471
NCIt 47 C2891
Orphanet 56 ORPHA99976
ICD10 via Orphanet 34 C15.2 C15.5
UMLS 69 C0004763

Summaries for Barrett Esophagus/esophageal Adenocarcinoma

NIH Rare Diseases : 50 barrett esophagus is a condition in which the lining of the esophagus (the tube that carries food from the throat to the stomach) is replaced by tissue that is similar to the lining of the intestines. although this change does not cause any specific signs or symptoms, it is typically diagnosed in people who have long-term gastroesophageal reflux disease (gerd). the exact underlying cause of barrett esophagus is not known; however, it generally occurs sporadically in people with no family history of the condition. treatment varies by the severity of the condition and generally includes medications and life style modifications to ease the symptoms of gerd. endoscopic or surgical treatments may be recommended in people with severe cases. last updated: 7/13/2015

MalaCards based summary : Barrett Esophagus/esophageal Adenocarcinoma, also known as barrett esophagus, is related to high-grade dysplasia in patients with barrett esophagus and prune belly syndrome, and has symptoms including esophageal carcinoma, barrett esophagus and chest pain. An important gene associated with Barrett Esophagus/esophageal Adenocarcinoma is ASCC1 (Activating Signal Cointegrator 1 Complex Subunit 1), and among its related pathways/superpathways are Glioma and Cell cycle. The drugs Abstral and Actiq have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and endothelial, and related phenotypes are digestive/alimentary and homeostasis/metabolism

OMIM : 54 Barrett esophagus, or Barrett metaplasia, describes the phenotypic change of normal esophageal squamous epithelium to a... (614266) more...

UniProtKB/Swiss-Prot : 66 Barrett esophagus: A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

Wikipedia : 71 Barrett\'s esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the... more...

Related Diseases for Barrett Esophagus/esophageal Adenocarcinoma

Diseases related to Barrett Esophagus/esophageal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
id Related Disease Score Top Affiliating Genes
1 high-grade dysplasia in patients with barrett esophagus 12.0
2 prune belly syndrome 11.8
3 emphysema, congenital lobar 11.6
4 mungan syndrome 11.2
5 benign exophthalmos syndrome 11.2
6 esophagus adenocarcinoma 11.1
7 visceral myopathy 11.0
8 leukoencephalopathy with vanishing white matter 11.0
9 lupus erythematosus tumidus 10.8
10 hodgkin lymphoma 10.8
11 leukemia 10.8
12 diarrhea 10.7
13 breast cancer 10.7
14 essential tremor 10.6
15 acute lymphocytic leukemia 10.6
16 multiple myeloma 10.6
17 adult t-cell leukemia 10.6
18 plasma cell leukemia 10.6
19 chronic lymphocytic leukemia 10.6
20 hepatitis 10.6
21 esophagitis 10.4
22 adenocarcinoma 10.4
23 clear cell adenofibroma 10.4 CDKN2A TP53
24 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53
25 skeletal tuberculosis 10.3 CCND1 CDKN2A
26 brachydactyly tibial hypoplasia 10.3 CCND1 CDKN2A PTGS2
27 oro-mandibular-limb hypogenesis syndrome 10.3 CCND1 CDKN2A TP53
28 urethral verrucous carcinoma 10.3 CDKN2A PTGS2 TP53
29 active vestibular meniere's disease 10.3 CCND1 CDKN2A PTGS2
30 neuroendocrine tumor 10.3 CDX2 KRT20 PTGS2
31 brain stem medulloblastoma 10.3 CCND1 CDKN2A TP53
32 cervical verrucous carcinoma 10.3 CCND1 CDKN2A TP53
33 giant cell tumor 10.3 CDX2 KRT20 TP53
34 tamoxifen-related endometrial lesion 10.3 CDKN2A PTGS2 TP53
35 neurofibrosarcoma 10.3 CDX2 KRT20 MUC2
36 cushing's syndrome 10.3 ATP4A CDX2 PTGS2
37 spinal cord oligodendroglioma 10.3 CDKN2A KRT20 TP53
38 estrogen-receptor positive breast cancer 10.3 CCND1 CDKN2A TP53
39 radiculopathy 10.3 KRT20 KRT7
40 adult myxoid chondrosarcoma 10.3 KRT20 KRT7
41 small intestine carcinoid neuroendocrine tumor 10.3 KRT20 MUC2 TP53
42 pericardium leiomyoma 10.3 CDKN2A TP53
43 uterine cervix leukoplakia 10.3 CDKN2A FHIT TP53
44 congenital diaphragmatic hernia 10.3 ATP4A PTGS2
45 choroid epithelioid cell melanoma 10.3 CDX2 MUC2 MUC5AC
46 suppurative lymphadenitis 10.3 CDKN2A KRT7
47 maxillary sinus cholesteatoma 10.3 CCND1 CDKN2A TP53
48 aicardi-goutieres syndrome 10.3 CDKN2A CDX2 MUC2 TP53
49 extraocular retinoblastoma 10.3 CCND1 CDKN2A TP53
50 connective tissue benign neoplasm 10.3 CCND1 CDKN2A TP53

Graphical network of the top 20 diseases related to Barrett Esophagus/esophageal Adenocarcinoma:



Diseases related to Barrett Esophagus/esophageal Adenocarcinoma

Symptoms & Phenotypes for Barrett Esophagus/esophageal Adenocarcinoma

Clinical features from OMIM:

614266

Human phenotypes related to Barrett Esophagus/esophageal Adenocarcinoma:

56 32 (show all 10)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 esophageal carcinoma 56 32 Very frequent (99-80%) HP:0011459
2 barrett esophagus 56 32 Very frequent (99-80%) HP:0100580
3 chest pain 56 Frequent (79-30%)
4 nausea and vomiting 56 Frequent (79-30%)
5 obesity 56 Very frequent (99-80%)
6 gastroesophageal reflux 56 Very frequent (99-80%)
7 feeding difficulties in infancy 56 Very frequent (99-80%)
8 cough 56 Frequent (79-30%)
9 lymphadenopathy 56 Occasional (29-5%)
10 clinodactyly of the 5th toe 56 Very frequent (99-80%)

UMLS symptoms related to Barrett Esophagus/esophageal Adenocarcinoma:


abdominal pain, constipation, coughing, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, snoring, sore throat, vertigo/dizziness, equilibration disorder, gastrointestinal gas

MGI Mouse Phenotypes related to Barrett Esophagus/esophageal Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.06 GAST MCM2 MUC2 MUC5AC PTGS2 TP53
2 homeostasis/metabolism MP:0005376 10.03 PTGS2 TP53 AMACR ATP4A CCND1 CDKN2A
3 endocrine/exocrine gland MP:0005379 9.91 ATP4A CCND1 CDKN2A CDX2 GAST MCM2
4 immune system MP:0005387 9.7 ATP4A CCND1 CDKN2A FHIT GAST MCM2
5 neoplasm MP:0002006 9.28 CCND1 CDKN2A CDX2 FHIT GAST MCM2

Drugs & Therapeutics for Barrett Esophagus/esophageal Adenocarcinoma

FDA approved drugs:

(show top 50) (show all 194)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Abstral 17 FENTANYL (citrate) ProStrakan Approved January 2011
2
Actiq 17 FENTANYL (citrate) Anesta Corporation Approved November 1998
3
Adcetris 17 46 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011
4
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
5
Akynzeo 17 46 NETUPITANT AND PALONOSETRON (hydrochloride) Helsinn Approved October 2014
6
Aloxi 17 46 PALONOSETRON (hydrochloride) MGI Pharma, Helsinn Healthcare Approved August 2003
7
Anexsia 17 ACETAMINOPHEN; HYDROCODONE BITARTRATE Mallinckrodt Group Approved August 1996
8
Aredia 17 46 PAMIDRONATE DISODIUM Chiron Approved August 1996
9
Arimidex 17 46 ANASTROZOLE AstraZeneca Approved January 1996
10
Aromasin Tablets 17 46 EXEMESTANE Pharmacia & Upjohn Approved October 21. 1999
11
Arranon 17 46 NELARABINE GlaxoSmithKline Approved October 2005
12
Beleodaq 17 46 BELINOSTAT Spectrum Pharmaceuticals Approved July 2014
13
Blincyto 17 46 BLINATUMOMAB Amgen Approved December 2014
14
Busulfex 17 46 BUSULFAN Orphan Medical Approved February 1999
15
Campostar 17 46 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn Approved June 1996
16
Cervarix 17 46 Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant GlaxoSmithKline Approved October 2009
17
Clolar 17 46 CLOFARABINE Genzyme Approved December, 2004
18
Cometriq 17 46 CABOZANTINIB S-MALATE Exelixis Approved November 2012
19
Degarelix 17 46 degarelix Ferring Pharmaceuticals Approved December of 2008
20
Elitek 17 46 RASBURICASE sanofi-aventis Approved October 2009
21
Ellence 17 46 EPIRUBICIN HYDROCHLORIDE Pharmacia & Upjohn Approved September 1999
22
Eloxatin 17 46 OXALIPLATIN Sanofi-aventis Approved August 2002
23
Erwinaze 17 46 asparaginase Erwinia chrysanthemi Eusa Pharma Approved November of 2011
24
Ethyol 17 AMIFOSTINE Alza Approved December 8, 1995
25
Eulexin 17 FLUTAMIDE Schering-Plough Approved June 1996
26
Evista 17 46 RALOXIFENE HYDROCHLORIDE Eli Lilly Approved September 2007
27
Farydak 17 46 PANOBINOSTAT LACTATE Novartis Approved February 2015
28
Faslodex 17 46 FULVESTRANT AstraZeneca Approved April 2002
29
Folotyn 17 46 PRALATREXATE Allos Therapeutics Approved September 2009
30
Fusilev 17 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals Approved March of 2008
31
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006
32
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
33
Gilotrif 17 46 AFATINIB DIMALEATE Boehringer Ingelheim Approved July 2013
34
Hycamtin 17 46 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham Approved October 2007/Approved May 1996
35
Ibrance 17 46 PALBOCICLIB Pfizer Approved February 2015
36
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
37
Imbruvica 17 46 IBRUTINIB Pharmacyclics Approved November of 2013/Approved February 2014
38
Inlyta 17 46 AXITINIB Pfizer Approved January 2012
39
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
40
Iressa 17 46 GEFITINIB AstraZeneca Approved May 2003
41
Istodax 17 46 ROMIDEPSIN Gloucester Pharmaceuticals Approved November 2009
42
Ixempra 17 46 IXABEPILONE Bristol-Myers Squibb Approved October 2007
43
Jevtana 17 46 CABAZITAXEL sanofi aventis Approved June 2010
44
Kadcyla 17 46 ADO-TRASTUZUMAB EMTANSINE Genentech Approved February 2013
45
Kadian 17 MORPHINE SULFATE Purepac Pharmaceutical Approved July 1996
46
Keytruda 17 46 PEMBROLIZUMAB Merck Approved September 2014
47
Kyprolis 17 46 CARFILZOMIB Onyx Pharmaceuticals Approved July 2012
48
Lazanda 17 FENTANYL CITRATE Archimedes Approved June 2011
49
Lenvima 17 46 LENVATINIB MESYLATE Eisai Approved February 2015
50
Leukine 17 SARGRAMOSTIM Immunex Approved on November 24, 1995/ Approved November 1996

Drugs for Barrett Esophagus/esophageal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 173)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Early Phase 1 73590-58-6 4594
4
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
5
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
6
Dinoprostone Approved Phase 4 363-24-6 5280360
7
Oxymetazoline Approved Phase 4 1491-59-4 4636
8
Phenylephrine Approved Phase 4 59-42-7 6041
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11 Liver Extracts Phase 4
12 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15
Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
17
Dexlansoprazole Phase 4,Phase 2 138530-94-6, 103577-45-3 9578005
18 Analgesics Phase 4,Phase 3,Phase 2
19 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
21 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2
22 Antipyretics Phase 4,Phase 3,Phase 2
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2
24 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2
25 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2
26 Fibrinolytic Agents Phase 4,Phase 3,Phase 2
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
28 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2
29 Anesthetics Phase 4,Early Phase 1
30 Neuroprotective Agents Phase 4,Phase 1
31 Antiemetics Phase 4
32 Antineoplastic Agents, Hormonal Phase 4,Early Phase 1
33 Autonomic Agents Phase 4
34 glucocorticoids Phase 4
35 Hormone Antagonists Phase 4,Phase 2,Early Phase 1
36 Hormones Phase 4,Phase 2,Early Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Early Phase 1
38 Methylprednisolone acetate Phase 4
39 Methylprednisolone Hemisuccinate Phase 4
40 Prednisolone acetate Phase 4
41 Prednisolone hemisuccinate Phase 4
42 Prednisolone phosphate Phase 4
43 Omega 3 Fatty Acid Nutraceutical Phase 4
44
Trioxsalen Approved Phase 2, Phase 3 3902-71-4 5585
45
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
46
Pantoprazole Approved Phase 3 102625-70-7 4679
47
Ranitidine Approved Phase 3 66357-59-3, 66357-35-5 3001055
48
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
49
acetic acid Approved, Nutraceutical Phase 2, Phase 3 64-19-7 176
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 11103-57-4, 68-26-8 445354

Interventional clinical trials:

(show top 50) (show all 232)
id Name Status NCT ID Phase
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients Completed NCT00352261 Phase 4
3 Barrett's Esophagus - 315 - 3 Way Cross-Over Completed NCT00637559 Phase 4
4 Barrett's Esophagus - 315 - 3 Way Cross Over Completed NCT00637988 Phase 4
5 Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation? Completed NCT01093755 Phase 4
6 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
7 Radiofrequency Ablation for the Treatment of Gastric Dysplasia Completed NCT01523912 Phase 4
8 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
9 Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids Recruiting NCT01733147 Phase 4
10 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
11 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4
12 Cryo Balloon for Residual Barrett's Esophagus Enrolling by invitation NCT02230410 Phase 4
13 Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus Terminated NCT00526786 Phase 4
14 A Trial Comparing Yield of Confocal Endomicroscopy Guided Biopsies Terminated NCT01030263 Phase 4
15 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Unknown status NCT00987857 Phase 3
16 Melatonin Associated to Acid Inhibition for Chemoprevention in Barret Esophagus: a Pilot Study Unknown status NCT01566474 Phase 3
17 Barrett's Esophagus & Gastroesophageal Reflux Disease Completed NCT00513331 Phase 2, Phase 3
18 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
19 "Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance Recruiting NCT02614703 Phase 2, Phase 3
20 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
21 ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study Recruiting NCT01915693 Phase 3
22 Biomarkers in Phototherapy of Barrett's Esophagus Active, not recruiting NCT00587600 Phase 2, Phase 3
23 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3
24 Esophageal Metaplasia Using a Novel Antibody: Reversibility by Proton Pump Inhibitor Terminated NCT00161200 Phase 3
25 Safety of Photodynamic Therapy (PDT) in the Ablation of High-grade Dysplasia (HGD) in Barrett's Esophagus (BE) Withdrawn NCT01209013 Phase 3
26 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
27 Screening for Barrett's Esophagus in Otolaryngology Patients Unknown status NCT00695227 Phase 2
28 Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT01447927 Phase 2
29 Novel Method of Surveillance in Barrett's Esophagus Completed NCT00955019 Phase 2
30 Confocal Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Early Esophageal Cancer(CEBE Study) Completed NCT01124214 Phase 2
31 Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus Completed NCT00474903 Phase 2
32 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
33 Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00005878 Phase 2
34 Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed NCT00003076 Phase 2
35 Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia Completed NCT01097304 Phase 2
36 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer Completed NCT00411151 Phase 2
37 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2
38 Photodynamic Therapy in Treating Patients With Early Esophageal Cancer Completed NCT00002935 Phase 2
39 Radiofrequency Ablation for Gastric Metaplasia and Dysplasia Completed NCT01614418 Phase 1, Phase 2
40 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction Completed NCT00086996 Phase 2
41 S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus Completed NCT00012363 Phase 2
42 S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach Completed NCT00004233 Phase 2
43 S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Completed NCT00096031 Phase 2
44 Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer Completed NCT00032123 Phase 2
45 Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus Recruiting NCT01298999 Phase 2
46 Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation Recruiting NCT02521285 Phase 2
47 Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium Recruiting NCT02249975 Phase 1, Phase 2
48 Autologous Cell Sheets Transplantation After ESD in the Esophagus Recruiting NCT02455648 Phase 2
49 Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia Active, not recruiting NCT01360541 Phase 2
50 YF476 in Barrett's Esophagus Enrolling by invitation NCT02597712 Phase 2

Search NIH Clinical Center for Barrett Esophagus/esophageal Adenocarcinoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: barrett esophagus

Genetic Tests for Barrett Esophagus/esophageal Adenocarcinoma

Genetic tests related to Barrett Esophagus/esophageal Adenocarcinoma:

id Genetic test Affiliating Genes
1 Barrett's Esophagus 29
2 Barrett Esophagus 24 MSR1 CTHRC1 ASCC1

Anatomical Context for Barrett Esophagus/esophageal Adenocarcinoma

MalaCards organs/tissues related to Barrett Esophagus/esophageal Adenocarcinoma:

39
Lung, Breast, Endothelial, Skin, Testes, Prostate, Heart

Publications for Barrett Esophagus/esophageal Adenocarcinoma

Variations for Barrett Esophagus/esophageal Adenocarcinoma

ClinVar genetic disease variations for Barrett Esophagus/esophageal Adenocarcinoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MSR1 NM_138715.2(MSR1): c.760C> G (p.Leu254Val) single nucleotide variant Pathogenic rs387906645 GRCh37 Chromosome 8, 16021631: 16021631
2 CTHRC1 NM_138455.3(CTHRC1): c.131A> C (p.Gln44Pro) single nucleotide variant Pathogenic rs387907029 GRCh37 Chromosome 8, 104384015: 104384015
3 ASCC1 NM_001198799.2(ASCC1): c.953A> G (p.Asn318Ser) single nucleotide variant Pathogenic rs146370051 GRCh37 Chromosome 10, 73892817: 73892817

Cosmic variations for Barrett Esophagus/esophageal Adenocarcinoma:

9 (show top 50) (show all 397)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3732832 ZNF341 oesophagus,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 9
2 COSM3732855 USH2A oesophagus,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 9
3 COSM3732707 USH2A oesophagus,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 9
4 COSM3732971 USH2A oesophagus,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 9
5 COSM3732767 USH2A oesophagus,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 9
6 COSM3732771 USH2A oesophagus,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 9
7 COSM1542406 TRIO oesophagus,NS,carcinoma,adenocarcinoma c.6611A>G p.K2204R 9
8 COSM10654 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.637C>T p.R213* 9
9 COSM10647 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.404G>T p.C135F 9
10 COSM43958 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.843C>T p.D281D 9
11 COSM44654 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.400T>C p.F134L 9
12 COSM10704 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.844C>T p.R282W 9
13 COSM6932 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.733G>A p.G245S 9
14 COSM10662 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.743G>A p.R248Q 9
15 COSM43564 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.708C>A p.Y236* 9
16 COSM6815 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.461G>T p.G154V 9
17 COSM10660 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.818G>A p.R273H 9
18 COSM10714 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.473G>T p.R158L 9
19 COSM43995 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.740A>T p.N247I 9
20 COSM10656 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 9
21 COSM10659 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.817C>T p.R273C 9
22 COSM10726 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.856G>A p.E286K 9
23 COSM44288 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.452C>T p.P151L 9
24 COSM43737 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.830G>A p.C277Y 9
25 COSM43846 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.487T>C p.Y163H 9
26 COSM44720 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.961A>T p.K321* 9
27 COSM43730 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.398T>G p.M133R 9
28 COSM11333 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 9
29 COSM10771 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.749C>T p.P250L 9
30 COSM10648 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 9
31 COSM10663 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 9
32 COSM43606 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.734G>A p.G245D 9
33 COSM44611 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.423C>A p.C141* 9
34 COSM10941 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.730G>A p.G244S 9
35 COSM10810 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.725G>T p.C242F 9
36 COSM12296 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.292C>T p.P98S 9
37 COSM43687 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.641A>G p.H214R 9
38 COSM44338 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.845G>A p.R282Q 9
39 COSM10690 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.473G>A p.R158H 9
40 COSM45883 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.470T>C p.V157A 9
41 COSM43665 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.746G>C p.R249T 9
42 COSM10867 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.797G>A p.G266E 9
43 COSM10808 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.488A>G p.Y163C 9
44 COSM44290 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.763A>G p.I255V 9
45 COSM10863 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.833C>T p.P278L 9
46 COSM45653 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.281C>G p.S94* 9
47 COSM44623 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.487T>A p.Y163N 9
48 COSM44700 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.556G>A p.D186N 9
49 COSM11183 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.799C>T p.R267W 9
50 COSM43683 TP53 oesophagus,NS,carcinoma,adenocarcinoma c.758C>T p.T253I 9

Copy number variations for Barrett Esophagus/esophageal Adenocarcinoma from CNVD:

7 (show top 50) (show all 157)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 21958 1 163432534 163614111 Gain and loss LMX1A Barrett''s syndrome
4 25140 1 184717073 186846060 Gain and loss PLA2G4A Barrett''s syndrome
5 25141 1 184717073 186846060 Gain and loss PTGS2 Barrett''s syndrome
6 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
7 33578 1 46425202 46624292 Loss RAD54L Barrett''s syndrome
8 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
9 39044 10 108165938 109275992 Loss SORCS1 Barrett''s syndrome
10 39081 10 109092539 133471230 Loss BUB3 Barrett''s syndrome
11 39082 10 109092539 133471230 Loss C10orf119 Barrett''s syndrome
12 39083 10 109092539 133471230 Loss NANOS1 Barrett''s syndrome
13 39407 10 114856262 115024106 Loss TCF7L2 Barrett''s syndrome
14 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
15 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
16 50933 11 120168346 133686875 Loss CHEK1 Barrett''s syndrome
17 50934 11 120168346 133686875 Loss ETS1 Barrett''s syndrome
18 50935 11 120168346 133686875 Loss TIRAP Barrett''s syndrome
19 52231 11 149520 6642613 Loss MUC6 Barrett''s syndrome
20 52232 11 149520 6642613 Loss RHOG Barrett''s syndrome
21 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
22 54793 11 474042 626401 Loss HRAS Barrett''s syndrome
23 54794 11 474042 626401 Loss MUPCDH Barrett''s syndrome
24 54795 11 474042 626401 Loss RASSF7 Barrett''s syndrome
25 54796 11 474042 626401 Loss RNH1 Barrett''s syndrome
26 54797 11 474042 626401 Loss SCT Barrett''s syndrome
27 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
28 57457 11 63400000 77100000 Gain EMS1 Esophageal adenocarcinoma
29 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
30 60370 11 8555485 8795697 Loss ST5 Barrett''s syndrome
31 60371 11 8555485 8795697 Loss STK33 Barrett''s syndrome
32 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
33 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
34 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
35 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
36 83864 14 22278370 23705612 Gain and loss MMP14 Barrett''s syndrome
37 83865 14 22278370 23705612 Gain and loss PCK2 Barrett''s syndrome
38 86372 14 58681498 106175506 Gain and loss FOXN3 Barrett''s syndrome
39 86373 14 58681498 106175506 Gain and loss MAX Barrett''s syndrome
40 86374 14 58681498 106175506 Gain and loss MLH3 Barrett''s syndrome
41 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
42 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
43 105274 16 77215302 77345302 Loss WWOX Barrett''s syndrome
44 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
45 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
46 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
47 108120 17 18863807 19044654 Loss GRAP Barrett''s syndrome
48 109777 17 2912016 3092354 Gain and loss Barrett''s syndrome
49 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
50 110805 17 34303536 34308523 Gain SCYA3 Esophageal adenocarcinoma

Expression for Barrett Esophagus/esophageal Adenocarcinoma

Search GEO for disease gene expression data for Barrett Esophagus/esophageal Adenocarcinoma.

Pathways for Barrett Esophagus/esophageal Adenocarcinoma

GO Terms for Barrett Esophagus/esophageal Adenocarcinoma

Biological processes related to Barrett Esophagus/esophageal Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC2 MUC6
2 replicative senescence GO:0090399 9.16 CDKN2A TP53
3 mitotic G1 DNA damage checkpoint GO:0031571 8.96 CCND1 TP53
4 O-glycan processing GO:0016266 8.8 MUC2 MUC5AC MUC6

Sources for Barrett Esophagus/esophageal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....